One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis.
Fourteen patients (aged 5.9-22.1 years) undergoing continuous ambulatory or cycling peritoneal dialysis were treated with recombinant human erythropoietin (rhEPO), which was given intravenously once a week at a dosage of 300 units/kg. The mean haematocrit level increased from 18.5% to 27.5% and the reticulocyte count from 19% to 62% within 1 month. After an average time of 3.1 months rhEPO dosage could be adjusted to 100 units/kg per week to keep the haematocrit level at 30%. Only 1 patient had an exacerbation of hypertension, which required a dosage reduction; other side-effects were not noted.
Offner
G
G
Department of Paediatric Nephrology and Metabolic Disorders, Childrens Hospital Medical School, Hannover, Federal Republic of Germany.
Hoyer
P F
PF
Latta
K
K
Winkler
L
L
Brodehl
J
J
Scigalla
P
P
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin